Back YahooFINANCE Share
Theralase Anti-Cancer Technology Effective for the Destruction of Lung Cancer
ACCESSWIRE ACCESSWIREAugust 8, 2017
TORONTO, ON / ACCESSWIRE / August 8, 2017 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSX-V: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds ("PDCs") to destroy cancer is pleased to announce that its lead compound, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to localize to and destroy various forms of lung cancer, when laser light activated, in an in-vitro and in an in-vivo animal model.
Lung cancer is the leading cancer killer in both men and women. Out of all lung cancers, Non-Small Cell Lung Cancer ("NSCLC") accounts for more than 85% of all lung cancers.
In 2016, an estimated 20,800 Canadians died from lung cancer, representing 26% of all cancer deaths, while an estimated 158,080 Americans died, representing 27% of all cancer deaths.
Current standard treatment for NSCLC is surgery followed by platinum-based chemotherapy, with an efficacy rate ranging between 15 to 30%.
A majority of all cancers demonstrate an upregulation of the transferrin receptor ("Tf-R"), as malignant cells require an abundance of iron (Fe3+) for proliferation; thus, the prevalence of the Tf-R has been directly correlated to increasing tumor: grade, stage, progression, and metastasis.
TLD-1433, in combination with transferrin (Rutherrin®) has been shown to selectively accumulate in cancerous tumors versus healthy tissue, due to localization through the Tf-R.
Each type of NSCLC has different kinds of cancer cells. The cancer cells of each type grow and spread in different ways. The types of NSCLC are named for the kinds of cells found in cancer and how the cells look under a microscope:
